Tri-legest Fe Kit
NDC Package 0555-9032-70

11-digit billing NDC: 00555903270 · Billing unit: EA · 5 EA per package

Package Information

Tri-legest Fe (norethindrone acetate and ethinyl estradiol) kits is tri-Legest® Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets [not USP]) is indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception.Tri-Legest® Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. This formulation utilizes a kit delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0555-9032 and is authorized under FDA application ANDA076105.

Identification & Billing

NDC Package Code
0555-9032-70
Package Description
5 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
00555903270
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
5 EA
RxNorm Crosswalk
  • RxCUI: 1358762 - norethindrone acetate 1 MG / ethinyl estradiol 0.02 MG Oral Tablet
  • RxCUI: 1358762 - ethinyl estradiol 0.02 MG / norethindrone acetate 1 MG Oral Tablet
  • RxCUI: 1358762 - ethinyl estradiol 20 MCG / norethindrone acetate 1 MG Oral Tablet
  • RxCUI: 1359130 - norethindrone acetate 1 MG / ethinyl estradiol 30 MCG Oral Tablet
  • RxCUI: 1359130 - ethinyl estradiol 0.03 MG / norethindrone acetate 1 MG Oral Tablet

Clinical Specifications

Proprietary Name
Tri-legest Fe 28 Day
Non-Proprietary Name
Norethindrone Acetate And Ethinyl Estradiol
Dosage Form
Kit - A packaged collection of related material.
Usage Information
Tri-Legest® Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets [not USP]) is indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception.Tri-Legest® Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tri-Legest® Fe should be used for the treatment of acne only if the patient desires a combined oral contraceptive for birth control and plans to stay on it for at least 6 months.Combined oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States.% of Women Experiencing an Unintended Pregnancy within the First Year of Use% of Women Continuing Use at One Year‡MethodTypical Use*Perfect Use†(1)(2)(3)(4)Chance§8585Spermicides¶26640Periodic Abstinence2563Calendar9Ovulation Method3Symptothermal#Þ2Post-ovulation1CapßParous Women402642Nulliparous Women20956SpongeParous Women402042Nulliparous Women20956Diaphragmß20656Withdrawal194CondomàFemale (Reality)21556Male14361Pill571Progestin only0.5Combined0.1IUDProgesterone T2.01.581Copper T380A0.80.678LNG 200.10.181Depo-Provera®0.30.370Norplant® and Norplant-2®0.050.0588Female Sterilization0.50.5100Male Sterilization0.150.10100Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%è.Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.ð Source: Trussell J, The Essentials of Contraception. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowel D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998.‡ Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year.* Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.† Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.§ The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. ¶ Foams, creams, gels, vaginal suppositories, and vaginal film.#Þ Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.ß With spermicidal cream or jelly.à Without spermicides.è The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of combined oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 light-orange pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow pills).ð However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age.Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator’s global evaluation. Patients with severe androgen excess were not studied.Table 3. Acne Vulgaris Indication Pooled Data 376 to 403 and 376 to 404 Observed Means at Six Months and at Baseline* Intent To Treat Population Norethindrone Acetate and EthinylEstradiol TabletsN = 296PlaceboN = 295Difference in Counts Between NorethindroneAcetate and EthinylEstradiol Tablets and Placebo at Six Months (95% CI)†Number of LesionsCounts% reductionCounts% reductionINFLAMMATORY LESIONSBaseline Mean2929Six Month Mean1452%1741%3 (±2)NON-INFLAMMATORY LESIONSBaseline Mean4443Six Month Mean2738%3225%5 (±3.5)TOTAL LESIONSBaseline Mean7472Six Month Mean4243%4932%7 (±5)*Numbers rounded to nearest integer†Limits for 95% Confidence Interval; not adjusted for baseline differencesNorethindrone acetate and ethinyl estradiol tablets users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment.Figure 2. Mean Percent Reduction in Total Lesion Counts From Baseline to Each 28-Day Cycle and Mean Total Lesion Counts at Each Cycle Following Administration of Norethindrone acetate and ethinyl estradiol tablets and Placebo (Statistically significant differences were not found in both studies individually until cycle 6)

Regulatory & Marketing

Labeler Name
Teva Pharmaceuticals Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA076105
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-26-2007
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0555-9032-70 identifies a specific commercial package of 5 blister pack in 1 carton / 1 kit in 1 blister pack of Tri-legest Fe 28 Day, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on October 26, 2007. The current certification is valid through December 31, 2026.

How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00555903270. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0555-9032-70
11-Digit CMS (5-4-2)
00555-9032-70

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.